ACAD Q2 2017 Earnings — ACADIA Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

ACADACADIA Pharmaceuticals Inc.

$4B

Q2 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$30M+31317.5% YoY

Gross Profit

$27M89.5% margin

Operating Income

-$68M-224.6% margin

Net Income

-$67M-221.3% margin

EPS (Diluted)

$-0.55

QoQ Revenue Growth

+99.4%

Cash Flow

Operating Cash Flow

-$59M

Free Cash Flow

-$59M

Stock-Based Comp.

$18M

Balance Sheet

Total Assets

$456M

Total Liabilities

$41M

Stockholders' Equity

$415M

Cash & Equivalents

$144M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$30M	$97,000	+31317.5%
Gross Profit	$27M	-$677,000	+4127.9%
Operating Income	-$68M	-$72M	+4.9%
Net Income	-$67M	-$71M	+5.4%